IMPLEMENTING BIOMARKER DEVELOPMENT IN DENMARK

In the second of a series of blogs for Precision Medicine Forum focusing on biomarker opportunities in Denmark; Peter Olesen, President ActiFoods ApS & Chairman European Institute of Innovation and Technology, outlines the country’s perspective into biomarker research.

The Danish government-funded project Biomarkers as an emerging growth area in Denmark aims to connect major public and private stakeholders to help implement a biomarker supported personalised medicine approach to significantly improve both the public healthcare system and the research, innovation and business environment of biomarker development and validation.

The Public-Private-Partnership model aims to facilitate cross-disciplinary collaboration, connecting:

  • The classical biotech and life sciences R&D dimension;
  • ICT and the digital transformation;
  • Companion diagnostics and clinical development;
  • Patients’ needs and involvement.

As well as an extensive portfolio of knowledge sharing, showcasing and matchmaking activities, the main outcome of the project will be a white paper illustrating the needs, opportunities and barriers for biomarker development, validation and clinical study from a Danish perspective.

The white paper will list recommended actions to be used in the public-private innovation interphase – with a focus on developing tailored solutions towards patient/citizen needs. In this context, we will develop a blueprint for the creation of a national centre or infrastructure of biomarker development and validation connecting public and private stakeholders, open to committed participants, and addressing how to implement the major recommendations.

This blueprint is being developed with two main approaches:

  1. A series of stakeholder mappings identifying strengths, opportunities, needs and barriers from the perspective of companies (both technology and pharma representatives), universities, hospitals, CROs, health professionals, patient organisations, health professionals and relevant innovation cluster and network organisations.
  2. Input and experiences gathered at project study visits to organisations and researchers in Germany, the Netherlands and Israel as well as desktop studies and analyses of developments in other countries.

Kim Holmstrøm, Research and Development Manager at Bioneer A/S will be speaking further on this subject as part of the Nordic Precision Medicine Forum in March. You can register for the event here.